Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.

[1]  T. Olsson,et al.  Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis , 2000, Journal of Neuroimmunology.

[2]  A. Gnasso,et al.  Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[3]  A M Zeiher,et al.  Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. , 2000, Circulation research.

[4]  S. Loening,et al.  Matrix‐metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma , 2000, International journal of cancer.

[5]  I. Ebihara,et al.  Elevation of Serum Levels of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-1 and Type IV Collagen, and Plasma Levels of Metalloproteinase-9 in Polycystic Kidney Disease , 2000, American Journal of Nephrology.

[6]  A. Clowes,et al.  Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. , 1999, Circulation research.

[7]  H Yonas,et al.  Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. , 1999, Stroke.

[8]  H. Kuivaniemi,et al.  Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. , 1999, Biochemical and biophysical research communications.

[9]  A. Henney,et al.  Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2–13.1 , 1999, Human Genetics.

[10]  T. Seifert,et al.  Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis , 1999, Journal of Neuroimmunology.

[11]  Y. Nakamura,et al.  Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. , 1999, Cancer research.

[12]  T. K. Hunt,et al.  Impaired wound contraction in stromelysin-1-deficient mice. , 1999, Annals of surgery.

[13]  K. Sirotkin,et al.  dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.

[14]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[15]  Y. Sasaguri,et al.  Shortened microsatellite d(CA)21 sequence down‐regulates promoter activity of matrix metalloproteinase 9 gene , 1999, FEBS letters.

[16]  L. Matrisian,et al.  Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.

[17]  A. Nagano,et al.  Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis. , 1999, Rheumatology.

[18]  C. Iwai,et al.  Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. , 1999, Circulation.

[19]  A. Henney,et al.  Human stromelysin gene promoter activity is modulated by transcription factor ZBP‐89 , 1999, FEBS letters.

[20]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[21]  A. Zwinderman,et al.  Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. , 1999, The American journal of cardiology.

[22]  E. Mochan,et al.  Identification of a Cytokine-induced Repressor of Interleukin-1 Stimulated Expression of Stromelysin 1 (MMP-3)* , 1999, The Journal of Biological Chemistry.

[23]  J. Rutter,et al.  Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter , 1999, British Journal of Cancer.

[24]  S. Zucker,et al.  Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. , 1999, The Journal of rheumatology.

[25]  W. Pearce,et al.  Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. , 1999, Journal of vascular surgery.

[26]  T. Iizasa,et al.  Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. D’Armiento,et al.  Epidermal expression of collagenase delays wound-healing in transgenic mice. , 1998, The Journal of investigative dermatology.

[28]  J. Gusella,et al.  A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. , 1998, Cancer research.

[29]  L. Brooks,et al.  A DNA polymorphism discovery resource for research on human genetic variation. , 1998, Genome research.

[30]  J. Hardy,et al.  Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. , 1998, Human molecular genetics.

[31]  T. Ueno,et al.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[32]  P. Talmud,et al.  The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. , 1998, Atherosclerosis.

[33]  F. Pasquier,et al.  A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. , 1998, Human molecular genetics.

[34]  M. Fini,et al.  Regulation of Matrix Metalloproteinase Gene Expression , 1998 .

[35]  H. Nagase.  Stromelysins 1 and 2 , 1998 .

[36]  J. Woessner,et al.  The Matrix Metalloproteinase Family , 1998 .

[37]  J. Morris,et al.  A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia , 1998, Nature Genetics.

[38]  S. Loening,et al.  Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase‐1 and the complex of metalloproteinase‐1/tissue inhibitor in plasma of patients with prostate cancer , 1997, International journal of cancer.

[39]  P. Libby,et al.  Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. , 1997, Circulation.

[40]  Y. Kodera,et al.  Plasma concentration of matrix metalloproteinase 9 in gastric cancer , 1997, The British journal of surgery.

[41]  M. Diaz-Meco,et al.  Cross-talk between Different Enhancer Elements during Mitogenic Induction of the Human Stromelysin-1 Gene* , 1996, The Journal of Biological Chemistry.

[42]  A. Henney,et al.  Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression* , 1996, The Journal of Biological Chemistry.

[43]  M J Davies,et al.  Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. , 1995, European heart journal.

[44]  A D Roses,et al.  Apolipoprotein E and Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Steed,et al.  Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease , 1995, Annals of human genetics.

[46]  A. Henney,et al.  Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. , 1994, British heart journal.

[47]  S. Zucker,et al.  Elevated plasma stromelysin levels in arthritis. , 1994, The Journal of rheumatology.

[48]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[49]  M. Reidy,et al.  Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. , 1994, Journal of vascular surgery.

[50]  H. Nagase,et al.  Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[51]  L. Matrisian,et al.  Structure and expression of the human gene for the matrix metalloproteinase matrilysin. , 1994, The Journal of biological chemistry.

[52]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[53]  A. Henney,et al.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  L. Matrisian,et al.  Metalloproteinases and their inhibitors in matrix remodeling. , 1990, Trends in genetics : TIG.

[55]  M. Karin,et al.  Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor , 1987, Cell.

[56]  R. Mahley,et al.  Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. , 1982, The Journal of biological chemistry.